Table 1.
N = 96 | Prior to chemotherapy | After chemotherapy | ||
---|---|---|---|---|
Tumor size | cT1 | 1 (1%) | ypT0 | 6 (6%) |
-a | ypT1 | 20 (21%) | ||
-b | -a | 2 | ||
-c | 1 | -b | 11 | |
cT2 | 25 (26%) | -c | 7 | |
cT3 | 22 (23%) | ypT2 | 31 (32%) | |
cT4 | 41 (43%) | ypT3 | 24 (25%) | |
-b | 19 | ypT4 | 7 (7%) | |
-d | 22 | -b | 6 | |
NA | 7 (7%) | -d | 1 | |
No surgery | 8 (9%) | |||
Nodal status | cN0 | 10 (11%) | pN0 | 25 (26%) |
cN1 | 62 (64%) | pN1 | 27 (28%) | |
cN2 | pN2 | 12 (12%) | ||
cN3 | 3 (3%) | pN3 | 14 (15%) | |
no surgery | 8 (9%) | |||
NA | 21 (22%) | NA | 10 (10%) | |
ER status | Positive | 68 (71%) | Positive | 59 (62%) |
Negative | 25 (26%) | Negative | 16 (17%) | |
NA | 3 (3%) | NA | 21 (21%) | |
(ypT0 or no surgery) | ||||
PR status | Positive | 59 (62%) | Positive | 46 (48%) |
Negative | 34 (35%) | Negative | 29 (31%) | |
NA | 3 (3%) | NA | 21 (21%) | |
(ypT0 or no surgery) | ||||
HER2 status | Positive | 28 (29%) | Positive | 18 (19%) |
Negative | 65 (68%) | Negative | 57 (60%) | |
NA | 3 (3%) | NA | 21 (21%) | |
ypT0, no surgery |
Abbreviations: NA not available, ER estrogen receptors, PR progesteron receptors.